1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Everest Medicines Limited
  6. News
  7. Summary
    1952   KYG3224E1061

EVEREST MEDICINES LIMITED

(1952)
  Report
Delayed Hong Kong Stock Exchange  -  05/27 04:08:54 am EDT
20.15 HKD   +1.66%
05/24Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis
PR
04/07Everest Medicines to Form Vaccine JV With China Resources Pharmaceutical
MT
04/06Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Everest Medicines Unit Secures Global License to Products, Tech for Coronavirus Treatment; Shares Rise 3%

01/13/2022 | 08:43pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
EVEREST MEDICINES LIMITED 1.66% 20.15 Delayed Quote.-43.05%
MSCI SINGAPORE (GDTR) 0.97% 5632.99 Real-time Quote.-11.14%
All news about EVEREST MEDICINES LIMITED
05/24Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstra..
PR
04/07Everest Medicines to Form Vaccine JV With China Resources Pharmaceutical
MT
04/06Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent ..
CI
04/05Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent ..
PR
03/31Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan
CI
03/28Everest Medicines Narrows Loss as General, Administrative Expenses Fall in 2021
MT
03/28TRANSCRIPT : Everest Medicines Limited, 2021 Earnings Call, Mar 29, 2022
CI
03/28Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021
PR
03/28Everest Medicines Limited Appoints Leah Liu as Joint Company Secretary
CI
03/21Calliditas Therapeutics AB - Updated regulatory plans for NEFECON in China
AQ
More news
Analyst Recommendations on EVEREST MEDICINES LIMITED
More recommendations
Financials
Sales 2022 193 M 28,8 M 28,8 M
Net income 2022 -1 095 M -163 M -163 M
Net cash 2022 873 M 130 M 130 M
P/E ratio 2022 -4,65x
Yield 2022 -
Capitalization 5 110 M 763 M 763 M
EV / Sales 2022 22,0x
EV / Sales 2023 2,59x
Nbr of Employees 405
Free-Float 100%
Chart EVEREST MEDICINES LIMITED
Duration : Period :
Everest Medicines Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVEREST MEDICINES LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 17,20 CNY
Average target price 34,67 CNY
Spread / Average Target 102%
EPS Revisions
Managers and Directors
Kerry Levan Blanchard Chief Executive Officer & Executive Director
Ian Ying Woo President, CFO & Executive Director
Wei Fu Executive Chairman
Xinhui Hu Chief Technology Officer
Jennifer Yang Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
EVEREST MEDICINES LIMITED-43.05%763
CSL LIMITED-7.17%92 708
SAMSUNG BIOLOGICS CO.,LTD.-7.64%47 463
BIOGEN INC.-14.05%30 198
WUXI BIOLOGICS (CAYMAN) INC.-45.27%29 183
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-32.02%20 229